Differential intrahepatic integrated HBV DNA patterns between HBeAg-positive and HBeAg-negative chronic hepatitis B

Daryl T-Y Lau1, Elena S Kim2, Zhili Wang3

  • 1Liver Center, Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA dlau@bidmc.harvard.edu ying-hsiu.su@bblumberg.org guoh4@upmc.edu.

Gut
|April 24, 2026
PubMed

Insights

In chronic hepatitis B (CHB), integrated hepatitis B virus DNA (iDNA) is a key source of hepatitis B surface antigen (HBsAg) in HBeAg(-) patients. This suggests iDNA plays a crucial role in HBsAg production and disease progression.

Area of Science:

  • Hepatology
  • Virology
  • Molecular Biology

Background:

  • Hepatitis B surface antigen (HBsAg) production in chronic hepatitis B (CHB) can originate from intrahepatic covalently closed circular DNA (cccDNA) and integrated hepatitis B virus DNA (iDNA).
  • Understanding the distinct roles of cccDNA and iDNA is crucial for managing CHB.

Purpose of the Study:

  • To investigate and compare the levels and characteristics of cccDNA and iDNA in the liver tissues of treatment-naive CHB patients with different hepatitis B e antigen (HBeAg) statuses.
  • To determine the primary source of HBsAg in HBeAg-negative CHB patients.

Main Methods:

  • Analysis of liver tissues from 24 HBeAg(+) and 32 HBeAg(-) treatment-naive CHB participants.
  • Quantification of cccDNA using real-time PCR after specific enzymatic digestion.
  • Detection of iDNA and HBV-host junction sequences via HBV hybridization-targeted next-generation sequencing.

Main Results:

  • HBeAg(-) CHB patients exhibited high HBsAg staining despite low cccDNA levels, indicating iDNA as a potential major HBsAg source.
  • A significant proportion (78.1%) of HBeAg(-) CHB patients had >50% iDNA of total HBV DNA.
  • iDNA integrations were frequently clustered in the DR2-DR1 region in HBeAg(-) CHB (52.4%), suggesting selection advantage.

Conclusions:

  • iDNA is likely the primary source of HBsAg in HBeAg(-) CHB, contributing to high HBsAg levels.
  • The preferential integration and expansion of iDNA at the DR2-DR1 locus in HBeAg(-) CHB may influence disease natural history.
  • These findings highlight the importance of targeting iDNA for effective CHB therapy.
Abstract